MOREPEN LABORATORIES LTD. Q1 FY27 Results

Morepen Laboratories posted consolidated revenue of ₹570.1 Cr for Q1 FY27 (quarter ended June 30, 2026), up 34.1% YoY and 17.6% QoQ — its highest-ever quarterly revenue, as management itself flagged. Consolidated PAT attributable to the parent came in at ₹56.4 Cr, up 424.8% YoY (₹10.7 Cr in Q1 FY26) and 258.2% QoQ (₹15.7 Cr in Q4 FY26), with EPS at ₹1.03 versus ₹0.20 a year ago. Neither the current nor the year-ago quarter carried any exceptional items on the face of the results, so this is organic, like-for-like growth rather than a base-effect or one-off distortion. Standalone PAT of ₹54.0 Cr (EPS ₹0.99) grew even faster YoY (+569.8%) than the consolidated number, indicating the subsidiaries' combined profit contribution to the group shrank slightly versus a year ago even as the parent itself accelerated.

The profit surge was driven almost entirely by margin expansion rather than one-offs: consolidated PBT margin nearly quadrupled to 13.1% of revenue from 3.65% a year ago and 4.80% last quarter, while net margin (PAT/total income) rose to 9.8% from 2.50% YoY and 3.19% QoQ. Cost of materials, the largest expense line, grew slower than revenue (up ~38% YoY versus 34% revenue growth is close, but total expenditure overall rose only ~20.9% YoY against 34.1% revenue growth), producing clear operating leverage. Finance costs and depreciation rose only modestly, so the margin gain sits mainly in gross/operating cost lines rather than below-the-line items.

The stock went into the print at ₹69.18, up 13.8% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.

Management's own press release frames the quarter as validation of a business-model shift: from a "transaction-led API business to a more focused, manufacturing-led platform," citing the ₹825 Cr CDMO mandate entering "full scale commercial execution" and recovering API profitability with export growth, both consistent with the margin and revenue numbers reported here. There is no formal prior guidance on record from the company or in our database to grade this print against, and no consensus street estimate for revenue or PAT for this quarter turned up in a web search — pre-result commentary from JM Financial and ICICI Securities held Neutral ratings (₹58 and ₹52 targets respectively) with both flagging the CDMO ramp's margin impact as the swing factor, which this print answers affirmatively but without a quantified consensus to benchmark against.